Consensus Haemonetics Corporation

Stocks

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 16:00:02 2026-10-12 EDT			5-day change	1st Jan Change
122.06 ^USD	+2.84%		+16.60%	+52.29%

10-09	Barrington Adjusts Price Target on Haemonetics to $140 From $118, Keeps Outperform Rating	MT
10-08	CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform	MT

Evolution of the Average Target: Haemonetics Corporation

Evolution of the Target Price: Haemonetics Corporation

Changes in Analyst Recommendations: Haemonetics Corporation

526b2.hPk_ccwH4LHsY4SeMPwWTmUn2KaW0ie4tuT4s-AkjK4.4pF9FqtfpOKHCsL0QsxVHVJSnpKlhG7vw9Cc_pgVy8_9yEgHjn6Q14g39w~f2cc5214a8410a172e62102f165df627

Analysts' recommendations: Haemonetics Corporation

10-09	Barrington Adjusts Price Target on Haemonetics to $140 From $118, Keeps Outperform Rating	MT
09-17	Haemonetics Shares Rise After Citigroup Upgrade	MT
09-17	Citigroup Upgrades Haemonetics to Buy From Neutral, Adjusts Price Target to $123 From $92	MT
08-19	Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating	MT
08-13	BofA Securities Adjusts Price Target on Haemonetics to $100 From $93	MT
08-12	BofA Securities Adjusts Haemonetics Price Target to $100 From $93	MT
08-07	Barrington Research Adjusts Haemonetics PT to $95 From $89, Maintains Outperform Rating	MT
05-22	Haemonetics Likely to See Upside as Core Businesses Improve, BofA Securities Says	MT
05-22	BofA Securities Upgrades Haemonetics to Buy From Neutral, Price Target is $80	MT
05-12	Barrington Cuts Price Target on Haemonetics to $89 From $94, Keeps Outperform Rating	MT
01-12	Barrington Adjusts Price Target on Haemonetics to $93 From $90, Maintains Outperform Rating	MT
12-15	Needham Downgrades Haemonetics to Hold From Buy, Removes $78 Price Target	MT
12-11	Citigroup Downgrades Haemonetics to Neutral From Buy, Adjusts PT to $88 From $77	MT
11-07	Haemonetics Taking Prudent View on Guidance After Plasma Recovery, BofA Says	MT
11-07	BofA Securities Upgrades Haemonetics to Neutral From Underperform, Raises Price Target to $75 From $58	MT
11-07	Needham Raises Price Target on Haemonetics to $78 From $68, Keeps Buy Rating	MT
25-08-11	Haemonetics Shares Fall After Raymond James Downgrade	MT
25-08-11	Raymond James Downgrades Haemonetics to Outperform From Strong Buy	MT
25-08-08	Haemonetics Shares Fall After JPMorgan Downgrade	MT
25-08-08	Needham Cuts Price Target on Haemonetics to $68 From $84, Keeps Buy Rating	MT
25-08-08	JPMorgan Downgrades Haemonetics to Neutral From Overweight, Adjusts Price Target to $62 From $85	MT
25-07-09	Haemonetics Shares Rise After Upgrade From Citigroup	MT
25-07-09	Citigroup Upgrades Haemonetics to Buy From Neutral, Lifts Price Target to $90 From $71	MT
25-07-09	Analyst recommendations: Illumina, Freeport-McMoran, XPO, T-Mobile US…
25-06-26	Baird Initiates Coverage on Haemonetics With Outperform Rating, $87 Price Target	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	HAEMONETICS CORPORATION					+2.96%
	ABBOTT LABORATORIES					+21.2%
	MEDTRONIC PLC					+18.04%
	STRYKER CORPORATION					+31.33%
	ESSILORLUXOTTICA					+53.03%
	CENCORA, INC.					+14.22%
	HOYA CORPORATION					+20.53%
	BECTON, DICKINSON AND COMPANY					+5.62%
	IDEXX LABORATORIES, INC.					+35.39%
	MEDLINE INC.					+22.51%
	Average					+22.48%
	Weighted average by Cap.					+24.57%